BRCA2 and prostate cancer: A recent study evaluating plasma cfDNA from 69 patients with advanced prostate cancer found that up to 10% of patients can have CHIP involving HRR genes (primarily ATM but also BRCA2 and CHEK2), suggesting a need for paired whole‐blood samples as a control to avoid misdiagnosis [73].